


The burden of antimicrobial resistance (AMR) in Sweden

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **700 lives** have been lost each year since 1990 in Sweden due to AMR.
- In 2021, there were an estimated **508 UI (421-595)** deaths attributable to AMR and **2,730 UI (2,280-3,180)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Escherichia coli* resistant to aminopenicillin, *Escherichia coli* resistant to trimethoprim-sulfamethoxazole and *Pseudomonas aeruginosa* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Sweden, a 10% reduction means to decrease the number of deaths associated with AMR to **2,580**, but currently the trend for this country could reach up to **6,540 UI [5,060-7,980]** AMR-associated deaths in 2030.

AMR in Sweden

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Sweden between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Sweden** in 2021, there were an estimated **508 UI (421-595)** deaths attributable to AMR and **2,730 UI (2,280-3,180)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Sweden has the 2nd lowest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

	Overall susceptible and resistant	Associated	Attributable
Burden rank	Staphylococcus aureus 2,340 UI (2,020-2,670) ↑	Escherichia coli 791 UI (652-931) ↓	Escherichia coli 139 UI (107-170) ↓
	Escherichia coli 1,460 UI (1,260-1,670) ↑	Staphylococcus aureus 446 UI (349-542) ↓	Pseudomonas aeruginosa 84 UI (63-105) ↓
	Pseudomonas aeruginosa 766 UI (661-872) ↓	Pseudomonas aeruginosa 330 UI (271-390) ↓	Staphylococcus aureus 73 UI (59-87) ↓
	Streptococcus pneumoniae 619 UI (533-705) ↓	Klebsiella pneumoniae 218 UI (167-269) ↓	Klebsiella pneumoniae 46 UI (35-58) ↓
	Klebsiella pneumoniae 542 UI (467-617) ↓	Enterococcus faecium 215 UI (183-246) ↑	Acinetobacter baumannii 36 UI (27-46) ↓
	Group A Streptococcus 414 UI (350-478) ↑	Streptococcus pneumoniae 142 UI (103-180) ↓	Enterococcus faecium 27 UI (15-38) ↑
	Enterococcus faecalis 266 UI (229-303) ↓	Proteus spp. 131 UI (97-165) ↑	Streptococcus pneumoniae 21 UI (15-27) ↓
	Enterococcus faecium 243 UI (208-277) ↑	Acinetobacter baumannii 103 UI (74-131) ↓	Enterobacter spp. 19 UI (15-22) ↓
	Proteus spp. 235 UI (201-270) ↑	Enterobacter spp. 74 UI (60-88) ↓	Proteus spp. 18 UI (13-23) ↓
	Enterobacter spp. 208 UI (179-237) ↓	Enterococcus faecalis 58 UI (49-68) ↓	Enterococcus faecalis 10 UI (7-13) ↓

Annualized rate of change (1990-2021):
 <-3% (dark blue), -1.5% to 0% (light blue), 1.5% to 3% (medium blue), >5.0% (dark red)
 -3% to -1.5% (medium blue), 0% to 1.5% (light blue), 3% to 5% (dark red)


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

	Associated	Attributable
Burden Rank	Escherichia coli Aminopenicillin 632 UI (387-877) ↓	Pseudomonas aeruginosa Carbapenems 45 UI (30-60) ↓
	Escherichia coli TMP-SMX 443 UI (346-540) ↑	Escherichia coli Aminopenicillin 29 UI (7-52) ↓
	Escherichia coli Beta-Lactam/Lactamase Inhib. 321 UI (252-391) ↓	Escherichia coli TMP-SMX 28 UI (15-40) ↑
	Escherichia coli Fluoroquinolones 318 UI (247-389) ↑	Klebsiella pneumoniae Aminoglycosides 25 UI (18-32) ↑
	Staphylococcus aureus Macrolides 287 UI (210-363) ↓	Pseudomonas aeruginosa Fluoroquinolones 24 UI (16-33) ↓
	Pseudomonas aeruginosa Carbapenems 226 UI (182-269) ↓	Escherichia coli Beta-Lactam/Lactamase Inhib. 24 UI (6-42) ↓
	Pseudomonas aeruginosa Fluoroquinolones 218 UI (175-262) ↓	Enterococcus faecium Fluoroquinolones 24 UI (12-35) ↑
	Klebsiella pneumoniae Aminoglycosides 207 UI (158-257) ↑	Escherichia coli Fluoroquinolones 23 UI (10-36) ↑
	Enterococcus faecium Fluoroquinolones 193 UI (163-223) ↑	Staphylococcus aureus Methicillin 20 UI (15-26) ↑
	Staphylococcus aureus Fluoroquinolones 177 UI (122-233) ↓	Staphylococcus aureus Vancomycin 20 UI (12-28) ↓

Annualized rate of change (1990-2021):
 <-3% (dark blue), -1.5% to 0% (light blue), 1.5% to 3% (medium blue), >5.0% (dark red)
 -3% to -1.5% (medium blue), 0% to 1.5% (light blue), 3% to 5% (dark red)

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) bloodstream infections (4,050 UI (3,490-4,610)), lower respiratory infection (excl. COVID) (3,610 UI (3,050-4,170)), peritoneal and intra-abdominal infections (1,410 UI (1,210-1,620)), diarrhea (884 UI (733-1,030)) and urinary tract infections and pyelonephritis (817 UI (682-951)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Sweden, people aged 70+ saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that 70+ continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the 70+ was 2,280 UI (1,880-2,680), whereas the mortality rate per 100,000 was 143 UI (118-168).

Data sources for Sweden

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Sweden by source type

Source type	Years	Sample size	Sample size units
Microbial or laboratory data without outcome	1990-2021	1,317,530	Isolates
Microbial or laboratory data with outcome	1990-2021	29,856	Isolates
Literature studies	1990-2021	2,688	Cases/isolates/susceptibility tests
Single drug resistance profile data	2010-2021	1,875,144	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care’s Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>